CE Mark for CoAp Pro device for treatment of mitral valve repair.- HeartStitch
HeartStitch has received its CE Mark in the European Union for its CoAp Pro device for treatment of mitral valve repair. This approval will provide physicians the ability to remodel the leaflets of the mitral valve and reestablish proper coaptation. The CoAp Pro expands HeartStitch's product line of cardiovascular devices, increasing the ability to provide surgeons and interventional cardiologists with a toolbox of solutions for treatment.
Prof. Dr. Achille Gaspardone, Director of Cardiology, Department of Medicine, Ospedale, S. Eugenio � ASL RMC, Rome Italy commented, "I am especially pleased to see HeartStitch receive this approval, because it provides the ability to use suture to remodel the mitral valves rather than the need to place a prosthetic device in the leaflets. In my opinion it is a significant advancement to the treatment of Mitral Regurgitation. Personally, I have seen the development of this device from its inception and have participated in the clinical testing, and with my extensive experience with the use of the NobleStitch� EL for PFO closure it was a natural evolution for me to use this technology."
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)